Welcome to our dedicated page for ROCKWELL MEDICAL SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKWELL MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKWELL MEDICAL's regulatory disclosures and financial reporting.
Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that President and CEO Mark Strobeck received an award of 30,000 shares of Common Stock as a grant, recorded at a price of $0.00 per share. Following this award, he directly beneficially owns 62,349 shares.
Footnotes explain that the award consists of restricted stock units that vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to his continued service. The company also effected a 1-for-10 reverse stock split effective at 12:01 AM on July 1, 2026, which reduced the number of shares held and proportionately adjusted outstanding equity awards, with post-transaction holdings already reflecting this split.
Rockwell Medical, Inc. is implementing a one-for-ten reverse stock split of its common stock. Effective at 12:01 a.m. Eastern Time on July 1, 2026, each ten existing shares will automatically combine into one new share, with no action required from stockholders.
No fractional shares will be issued; instead, holders will receive cash equal to the applicable fraction multiplied by the June 30, 2026 Nasdaq closing price, adjusted for the split. The common stock will continue trading on Nasdaq under the symbol RMTI and will trade on a split-adjusted basis with a new CUSIP. Proportionate adjustments will also be made to equity awards, preferred stock conversion terms and warrants, while authorized capital and par value remain unchanged.
Rockwell Medical, Inc. reported voting results from its 2026 annual shareholder meeting, where stockholders approved all four proposals, including elections, pay, auditor and capital structure changes.
Two Class II directors, Joseph Dawson and Joan Lau, Ph.D., were elected with 9,812,114 and 9,890,379 votes in favor, respectively. Stockholders endorsed executive compensation on an advisory basis with 8,232,918 votes for and ratified EisnerAmper LLP as auditor with 22,996,530 votes for. They also approved an amendment to the Certificate of Incorporation authorizing a reverse stock split of the common stock, with 16,993,038 votes for and 6,597,036 against.
Rockwell Medical, Inc. reported that Nasdaq notified the company on May 8, 2026 that its common stock no longer meets the Nasdaq Capital Market’s Minimum Bid Price Requirement, which requires a minimum closing bid price of $1.00 per share for 30 consecutive business days.
The notice does not immediately affect trading, and the shares will remain listed while Rockwell has 180 calendar days, until November 4, 2026, to regain compliance by having a closing bid price of at least $1.00 for ten consecutive business days. Rockwell has included a proposal for a reverse stock split in its 2026 proxy statement, which it believes could restore compliance if approved and implemented, though it cautions there is no assurance it will regain or maintain compliance or receive additional relief from Nasdaq.
Rockwell Medical, Inc. furnished an updated corporate presentation, dated May 7, 2026, for investor and public reference. The presentation is provided as Exhibit 99.1 under a current report. The material is furnished under Regulation FD, meaning it is not treated as filed for liability purposes.
Rockwell Medical, Inc. reported first-quarter 2026 results showing slightly lower sales but stable losses and improved cash use. Net sales were $17.3 million, down 8% from $18.9 million a year earlier, mainly from reduced DaVita purchases, partly offset by higher pricing and new customers.
Gross profit was $2.9 million with a 17% margin, similar to last year, and net loss was $1.6 million, or $0.04 per share. DaVita accounted for 7% of sales versus 27% in 2025, reducing customer concentration. Operating cash outflow improved sharply to about $0.2 million from $3.5 million.
Rockwell ended March 31, 2026 with $23.9 million in cash, cash equivalents and available-for-sale investments and working capital of $27.1 million. Management states these resources, plus $13.1 million remaining under its at-the-market equity program, are expected to fund operations for at least 12 months.
Rockwell Medical reported first quarter 2026 results showing mixed top-line but improving profitability metrics. Net sales were $17.3 million, down 8% from $18.9 million a year earlier, mainly due to lower purchasing by one customer. Gross profit was $2.9 million and gross margin improved slightly to 17% from 16%.
The company posted a net loss of $1.6 million, similar to the prior year, while Adjusted EBITDA improved to a loss of $0.3 million from a $0.4 million loss. Cash, cash equivalents and investments were $23.9 million. For 2026, Rockwell guides to net sales of $70–$75 million, gross margin of 18%–22%, Adjusted EBITDA of $1–$2 million, and positive operating cash flow, supported by pricing actions and operational changes expected to add over $3 million in annualized gross profit.
Rockwell Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 12, 2026. The agenda includes electing two Class II directors through 2029, an advisory vote on executive pay, ratifying EisnerAmper LLP as auditor, and approving a reverse stock split amendment.
Holders of 39,405,302 common shares as of April 16, 2026 can vote, with one vote per share. The proxy also details board structure, committee independence, executive employment terms, performance-based equity awards, severance and change-in-control protections, stock ownership guidelines, clawback policy, and anti-hedging and anti-pledging rules.
Rockwell Medical, Inc. has circulated a preliminary proxy statement for its 2026 Annual Meeting, to be held virtually on June 12, 2026. Items for shareholder vote include election of two Class II directors, an advisory vote on executive compensation, ratification of EisnerAmper LLP as auditor, and a proposal to amend the Certificate of Incorporation to effect a reverse stock split. Only holders of record on April 16, 2026 may vote. The Board recommends voting FOR all proposals. Proxy materials and the 2025 Annual Report are available at the virtual meeting website.